Skip to main content
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. — Investor Relations & Filings

Ticker · MAZE US Manufacturing
Filings indexed 137 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country US United States of America
Listing US MAZE

About Maze Therapeutics, Inc.

https://www.mazetx.com/

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Recent filings

Filing Released Lang Actions
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Regulatory Filings
2026-04-22 English
144 - Maze Therapeutics, Inc. (0001842295) (Subject)
Regulatory Filings
2026-03-30 English
10-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Annual Report FY 2025
2026-03-25 English
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Regulatory Filings
2026-03-25 English
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
Director's Dealing
2026-03-20 English
4 - MAZE THERAPEUTICS, INC. (0001842295) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.